Patents Assigned to Cancer Institute, Japanese Foundation for Cancer Research
  • Patent number: 5759833
    Abstract: Isolated, recombinant nucleic acids which encode an isoleucyl-tRNA synthetase (IleRS) of human origin have been used to make expression constructs and transformed host cells for the production of a recombinant human IleRS. A recombinant enzyme has been purified, and is active in the specific aminoacylation of tRNA by isoleucine. Isolated, recombinant enzyme, and antibodies made specifically thereto, can be useful in assays to diagnose and monitor the autoimmune disease known as "antisynthetase syndrome." The essential isoleucyl-tRNA synthetases of microbes pathogenic in humans can be the targets of inhibitory agents having antimicrobial activity. A human isoleucyl-tRNA synthetase, isolated and purified, can be used to assess the toxic effect in humans of such an inhibitory agent in various biochemical activity assays. This human enzyme can also be expressed in "tester strains," whose cells rely upon the function of the human isoleucyl-tRNA synthetase for tRNA.sup.Ile charging.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 2, 1998
    Assignees: Cubist Pharmaceuticals, Inc., Cancer Institute, Japanese Foundation for Cancer Research
    Inventors: Kiyotaka Shiba, Janice E. Kranz, Paul R. Schimmel
  • Patent number: 5629188
    Abstract: Isolated, recombinant nucleic acids which encode alanyl-tRNA synthetase (AlaRS) of human origin have been used to make expression constructs and transformed host cells for the production of recombinant human AlaRS. The recombinant enzyme has been purified, and is active in the specific aminoacylation of tRNA by alanine. The isolated, recombinant human AlaRS is also recognized by antibodies made by patients with the particular autoimmune disease known as "antisynthetase syndrome" in which the patients produce antibodies against the human alanyl-tRNA synthetase in their own cells. Thus, the isolated, recombinant enzyme, and antibodies made specifically thereto, can be useful in assays to diagnose and monitor this disease. The essential alanyl-tRNA synthetases of microbes pathogenic in humans can be the targets of inhibitory agents having antimicrobial activity.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: May 13, 1997
    Assignees: Cubist Pharmaceuticals, Inc., Cancer Institute, Japanese Foundation for Cancer Research, Massachusetts Institute of Technology
    Inventors: Kiyotaka Shiba, Paul R. Schimmel, Tracy L. Ripmaster
  • Patent number: 4788219
    Abstract: 5-((3,4-dimethoxyphenetyl)methylamino)- 2-(3,4-dimethoxy-phenyl)-2-isopropylvaleronitrile or a pharmaceutically acceptable salt thereof is effective to prevent metastasis of cancer.
    Type: Grant
    Filed: January 16, 1987
    Date of Patent: November 29, 1988
    Assignees: Cancer Institute, Japanese Foundation for Cancer Research, Eisai Co., Ltd.
    Inventors: Yoshio Sakurai, Takashi Tsuruo
  • Patent number: RE40948
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: October 27, 2009
    Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of Utah
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White